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Simple Summary: Colorectal cancer is the second leading cause of cancer-related death in the world.
Upregulation of fatty acid metabolism is a hallmark of cancer and recent studies demonstrate that
blocking fatty acid uptake is a promising therapeutic strategy. We have previously shown that CD36,
a transporter of fatty acid, promotes colorectal cancer tumor growth. We have also demonstrated
that high expression of CD36 is associated with cancer cells that are prone to metastasis. Here,
in studying the role of CD36 in colorectal cancer, we found that CD36 promotes colorectal cancer
invasion in vitro and metastasis in vivo and that overexpression of CD36 upregulates expression of
the matrix metalloproteinase MMP28. Our data demonstrates that MMP28 cleaves and decreases
expression of E-cadherin, a marker for epithelial-to-mesenchymal transition in colorectal cancers.
This newly defined CD36–MMP28–E-cadherin axis provides new therapeutic targets for the treatment
of colorectal cancer.
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Abstract: Altered fatty acid metabolism continues to be an attractive target for therapeutic intervention in cancer. We previously found that colorectal cancer (CRC) cells with a higher metastatic
potential express a higher level of fatty acid translocase (CD36). However, the role of CD36 in CRC
metastasis has not been studied. Here, we demonstrate that high expression of CD36 promotes
invasion of CRC cells. Consistently, CD36 promoted lung metastasis in the tail vein model and GI
metastasis in the cecum injection model. RNA-Seq analysis of CRC cells with altered expression
of CD36 revealed an association between high expression of CD36 and upregulation of MMP28, a
novel member of the metallopeptidase family of proteins. Using shRNA-mediated knockdown and
overexpression of CD36, we confirmed that CD36 regulates MMP28 expression in CRC cells. siRNAmediated knockdown of MMP28 decreases invasion of CRC cells, suggesting that MMP28 regulates
the metastatic properties of cells downstream of CD36. Importantly, high expression of MMP28 leads
to a significant decrease in active E-cadherin and an increase in the products of E-cadherin cleavage,
CTF1 and CTF2. In summary, upregulation of CD36 expression promotes the metastatic properties of
CRC via upregulation of MMP28 and an increase in E-cadherin cleavage, suggesting that targeting
the CD36–MMP28 axis may be an effective therapeutic strategy for CRC metastasis.
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1. Introduction
Colorectal cancer (CRC) is the leading cause of non-smoking-related cancer deaths
and the second leading cause of all cancer-related deaths in the United States, and indeed
the world [1,2]. Patients diagnosed with late-stage CRC (Stage III–IV), which exhibit local
invasion and distant metastatic disease, have nearly a 10-fold decrease in their 5-year
survival rate when compared to earlier stage, localized disease [3,4]. Despite advances in
the treatment of primary CRC, effective therapeutic strategies for late-stage CRC are lacking.
Altered fatty acid metabolism is recognized as a hallmark of cancer and multiple
studies suggest targeting this pathway as a potential therapeutic strategy for cancer including CRC [5–7]. Fatty acid translocase (CD36) plays a significant role in dietary fatty acid
regulation as an exogenous fatty acid transporter [8,9]. CD36 can be membrane bound,
where it can bind low-density lipoproteins and extracellular long-chain and ultra-longchain free fatty acids [8,10]. CD36 has been implicated in the promotion of primary tumor
proliferation and disease progression in multiple malignancies, including ovarian, glioblastoma, and breast cancers [11–14]. Recently, our laboratory has shown the important role of
CD36 in enhancing cellular proliferation and progression of primary CRC and identified
upregulation of CD36 as a potential mechanism of resistance to FASN-targeted therapy [15].
While compelling evidence exists to support CD36’s role in the promotion of primary tumor growth and progression in several cancers, some evidence also suggests that
CD36 may also play a critical role in cancer metastasis. CD36 was shown to promote oral
carcinoma migration and invasion in vitro and metastasis in vivo [16]. In fact, enhanced
presence of tumor cells expressing high levels of CD36 and increased metastatic potential is
associated with a poor prognosis and clinical outcome in both glioblastoma and oral carcinoma [13,16]. CD36 also enhances migration and invasion in gastric cancer cells in vitro as
well as local invasion and metastasis in ovarian cancer xenografts [11,12,17]. Furthermore,
CD36 has been shown to promote cell growth and metastasis as well as epithelial-tomesenchymal transition (EMT) in cervical cancer [18,19]. However, the potential role of
CD36 in CRC metastasis has not been previously studied.
EMT is the fundamental process through which an epithelial cell acquires a more
mesenchymal phenotype [20,21]. Aside from being utilized during normal tissue development, wound healing, and tissue repair, EMT has also been identified as one of the crucial
steps involved in cancer metastasis [22–24]. Various molecular pathways and markers are
implicated in the regulation of EMT in CRC, including Snail/Slug, Wnt/β-catenin and,
particularly, the downregulation of E-cadherin, a critical component of cell-cell adhesion
junctions [25]. Loss of E-cadherin is a key characteristic of EMT initiation in various cancers,
including CRC [26,27]. E-cadherin expression has previously been shown to be a good
prognostic marker for patients with CRC [28]. Furthermore, loss of E-cadherin increases
CRC cell invasion and is correlated with poor survival rates [29,30]. Lower expression of
E-cadherin in CRC patient tumors is associated with tumor differentiation, invasion depth,
tumor stage and lymph node metastasis [31]. Although E-cadherin has several known
transcriptional regulators, including Snail and Slug, it is suggested that E-cadherin is strictly
regulated post-transcriptionally in CRC, either through stabilization or cleavage [32,33].
The matrix metallopeptidase (MMP) family of proteins plays an important role in the
degradation of several extracellular matrix (ECM) components [34,35]. MMP28, one of
the newest members of this family of proteins to be identified, is associated with EMT in
lung carcinoma [36]. Furthermore, MMP28 is associated with a poor prognosis and lower
survival rates in gastric cancer and increased expression of MMP28 is associated with an
increase in invasion and colony formation of gastric cancer cells in vitro and in vivo [37,38].
Lastly, MMP28-induced EMT in lung carcinoma is associated with a significant loss of
E-cadherin expression [36,39].
Since previous studies have implicated CD36’s involvement in the metastatic process
and regulation of EMT in cancer, the goal of this study was to evaluate the contribution
of CD36 to CRC metastasis. We found that upregulation of CD36 promotes invasion and
colony formation of CRC cells in vitro. Consistently, high expression of CD36 is associated
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with a significant increase in metastasis in vivo. To address the potential mechanisms of
how CD36 regulates metastasis, we found that overexpression of CD36 is associated with
MMP28 expression in established CRC cell lines and isogenic patient-derived xenografts.
Our results also show that knockdown of MMP28 reduces CRC cell invasion in vitro. Lastly,
we found that CD36 and MMP28 expression are inversely associated with E-cadherin
expression in CRC cells. We show that a high level of MMP28 expression is associated
with an increase in the cleavage of E-cadherin and an increase in the cleavage products
C-terminus fragment 1 and 2 (CTF1 and CTF2).
Together these findings implicate that CD36 promotes metastasis via upregulation
of MMP28 and E-cadherin cleavage and, thus, may be a viable therapeutic target for the
treatment of metastatic CRC.
2. Materials and Methods
Established Colon Cancer and Isogenic Cell Lines. Established cell lines, HCT116,
HT29 and HT29LuM3, were maintained in McCoy’s 5A medium supplemented with 10%
FBS (Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin–streptomycin. HT29 LuM0
and LuM3 cell lines were established as previously described [40]. All cell lines were
authenticated using STR DNA profiling (Genetica, Cincinnati, OH, USA).
Stable CD36 knockdown HCT116 and HT29LuM3 cell lines were established using
CD36 shRNA from Sigma-Aldrich, St. Louis, MO, USA (TRCN0000057000 [shRNA#1];
TRCN0000419016 [shRNA#2]). pLKO.1-puro non-mammalian shRNA was used as a nontargeted control (NTC). Cells were selected with 10 mg/mL puromycin. Knockdown was
confirmed via quantitative real-time polymerase chain reaction (qRT-PCR) after cell selection and prior to performing in vitro and in vivo experiments. Overexpression cell lines
were established by transfecting HCT116 and HT29 LuM0 cells with either pLenti-C-MycDDK-P2A-Puro-CD36 overexpression (OriGene #RC221976L1V) or pLenti-C-Myc-DDKP2A-Puro-Empty-Vector (OriGene #PS1000064) lentiviral transduction particles. MMP28
knockdown cell lines were generated by transfecting CRC cells with scrambled siRNA
control (Invitrogen #12935200) or siMMP28 siRNA#1 and #2 (Invitrogen, HSS149127 and
HSS149128) in combination with Lipofectamine RNAiMAX Transfection Reagent (Thermo
Fisher #13778150). MMP28 knockdown was verified by qRT-PCR and Western blotting.
Cells were transfected for 48 h prior to commencement of in vitro experiments.
qRT-PCR. Total RNA was isolated using an RNeasy mini kit (QIAGEN). cDNA was
synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems,
Bedford, MA, USA; #4368814). qRT-PCR was carried out using a TaqMan Gene Expression
Master Mix (Applied Biosystems, Bedford, MA, USA; #4369016) according to manufacturer’s protocol and TaqMan probes for human CD36 (#4331182-Hs00169627_m1), MMP28
(#4331182-Hs00425232_g1), E-cadherin/CDH1 (#4331182-Hs01023895_m1) and GAPDH
(#4331182-Hs02786624_g1) from Thermo Fisher, Waltham, MA, USA.
RNA-Seq and Gene Set Enrichment Analysis. mRNA samples were analyzed via RNASeq by BGI Genomics, Cambridge, MA. Gene set enrichment analysis was performed by
the Biostatistics and Bioinformatics Shared Resource Facility at the University of Kentucky,
Lexington, KY. The gene set enrichment analysis was performed using GSEA software
(GSEA 4.0.3) and the KEGG pathways in the Molecular Signature Database (MSigDB) [41].
Trans-well Invasion Assay. HCT116 CD36 overexpression and CD36 knockdown cell
lines were plated and starved for 48 h on 100 mm petri dishes with McCoy’s 5A medium
without FBS supplementation. Corning 24-well BioCoat™ Matrigel® Invasion Chambers
(Corning #354480) were rehydrated for 2 h with McCoy’s 5A medium not supplemented
with FBS at 37 ◦ C. HCT116 cell lines were then trypsinized and counted using a Beckman
Coulter Vi-Cell BLU Cell Viability Analyzer (Beckman Coulter #C19196) and plated at
50,000 cells/chamber serum free with McCoy’s 5A medium. Invasion chambers were then
placed in wells containing 400 µL of McCoy’s 5A medium supplemented with 10% FBS as a
chemoattractant. Cell were allowed to invade for 48 h. Chambers were then aspirated, the
inside wiped with a cotton swab, and chambers stained with 0.1% crystal violet (Millipore
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sigma #C6158-50G) for 10 min. Invaded cells were counted in four representative fields
(counting grit) per well with an inverted macroscope. Chambers were also imaged and
then de-stained with 200 µL of extraction buffer from the CytoSelect Cell Invasion Assay
Kit (Cell Biolabs Inc., San Diego, CA, USA; #CBA-111-T). A total of 50 µL of extract from
each well was plated on a 96-well plate and absorbance was measured at 560 nm on a
microplate reader for cell invasion quantification.
Colony Formation Assay. 6-well cell culture plates were first layered with 2% soft agar
using SeaPlaqueTM GTG Agarose (Lonza #50115) melted in Milli-Q water. HCT116 and
HT29 LuM0 CD36 overexpressing cells were trypsinized and counted as described above.
Cells were mixed with a 1.5% soft agar and 2X McCoy’s 5A medium solution and plated
at a concentration of 5000 cells/well. McCoy’s 5A medium supplemented with 10% FBS
was placed on top of both agarose layers and the media levels monitored. Colonies were
allowed to grow for 14 days and then stained with 0.1% crystal violet (Millipore sigma
#C6158-50G) for 2 h at room temperature. Wells were then washed with Milli-Q water to
remove the excess crystal violet stain, imaged, and the colony diameter measured.
Confocal Microscopy. HT29-GFP-Luc, LuM0 and LuM3 cells were plated at a concentration of 10,000 cells/chamber onto u-Slide 8-well-chambered coverslips (Ibidi #80826)
in 400 µL McCoy’s 5A medium supplemented with 10% FBS for 48 h. Cells were then
fixed with 10% Formalin for 10 min followed by permeabilization with 1% Triton X. Cells
were then blocked with 1% bovine serum albumin (BSA) for 20 min at room temperature.
Cells were incubated with primary antibodies for CD36 (Santa Cruz # sc-7309) and MMP28
(Abcam #ab175937) in 1% BSA for 2 h at room temperature. Cells were then washed 3X
with PBS and incubated with fluorescent secondary antibodies (Thermo Fisher#) in 1% BSA
for 1 h at room temperature. The chambers were washed 3 times with PBS and incubated
with Hoechst and Phalloidin stains for 20 min. Chambers were then imaged using a Nikon
A1 Confocal Microscope.
FA Uptake Assay. HT29-GFP-Luc, LuM0 and LuM3 cells were plated at 10,000 cells/well
on an 8-well coverslip u-slide (Ibidi #80826) and treated with CD36 neutralizing antibody
(Cayman Chemical #10009893) at a concentration of 2 µg/mL for 24 h. Mouse IgA (Abcam
#37322) was used as a control. After incubation with neutralizing antibody, cells were then
treated with fluorescent FA analogue BODIPY™ 558/568 C12 (Thermo Fisher # D3835)
for 10 min in serum-free McCoy’s 5A medium supplemented with 10% fatty acid-free
BSA. Cells were washed twice with PBS and fixed with PBS containing 5% formalin for
20 min at 37 ◦ C. Cell were then imaged via confocal microscopy using a Nikon A1 Confocal
Microscope.
Tail-Vein Injections. For intravenous injection of CRC cells, NSG mice (NOD.Cg-Prkdc
Il2rg /SzJ) were anesthetized with isoflurane (induction 4%, maintenance 2%). The viability
of cells used for inoculation was >95% as determined by Vi-CELL™ XR (Beckman Coulter).
The HT29LuM3-GFP-Luc NTC (n = 5) and shCD36 (n = 5) cell lines were aliquoted in PBS
at a concentration of 1.0 × 106 cells/100 µL and injected via the tail vein into 6–8-week-old
mice. Gentle pressure was applied to the inoculation site until there was no visible sign
of bleeding. After 9 weeks, bioluminescent imaging using Lago (Spectral Instruments
Imaging; Tucson, AZ, USA) was employed to monitor the distribution and development of
lung metastasis. Prior to imaging, animals were anesthetized with 2% isoflurane inhalation
and images were acquired 10 min after i.p. injection of D-luciferin (150 mg/kg; 100 µL
per mouse). Bioluminescent signal was quantified in Aura software (Spectral Instruments
Imaging; Tucson, AZ, USA). GFP fluorescence imaging was performed using an LT-9500
Illumatool/TLS (Lightools Research, Encinitas, CA, USA), equipped with an excitation
source (470 nm) and filter plate (515 nm).
Cecum Injections. Cecum injections were performed as previously described [42].
HCT116 CD36 overexpression (n = 5) and control (n = 5) cells were aliquoted in PBS at a
concentration of 1.0 × 106 cells/50 µL and injected into the cecal wall of NU/NU mice.
After 10 weeks, the mice were sacrificed and gross examination/imaging of the tumor
burden within the cecum, colon and intestine was performed.
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** p < 0.01, *** p < 0.001, SEM.
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signaling as compared to mice injected with HT29 LuM3 NTC cells (Figure 3A). Furthermore, resected lungs from both NTC- and shCD36-injected mice show that mice injected
with HT29 shCD36 cells have substantially lower GFP signaling and tumor burden than
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metastasis
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(A) Representative
images
quantification of the bioluminescence imaging in tail‐vein‐injected mice of HT29 LuM3 GFP‐Lucif‐
and quantification of the bioluminescence imaging in tail-vein-injected mice of HT29 LuM3 GFPerase cells, NTC (n = 5) and CD36shRNA (n = 5). (B) GFP imaging and (C) H&E staining of lung
Luciferase cells, NTC (n = 5) and CD36shRNA (n = 5). (B) GFP imaging and (C) H&E staining of
tissues of resected lungs of the tail‐vein‐injected mice. (D) qRT‐PCR quantification of CD36 in the
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of resected
lungsRNA
of thecell
tail-vein-injected
mice.
quantification of CD36
HT29 LuM3 GFP‐Luciferase
and CD36sh
lines. (E) Images
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HCT116 control
in the HT29 LuM3 GFP-Luciferase NTC and CD36sh RNA cell lines. (E) Images from the HCT116
control and CD36 overexpression cecum-injected mice, showing increased tumor burden and colon
metastasis in the CD36 overexpression mice. (F) Hematoxylin and eosin staining of the resected
primary and metastatic tissues from mice injected with control and CD36 overexpression HCT116
cells. M—metastasis. (G) The rate of occurrence of primary cecum tumor and GI metastasis in mice
based on gross examination. (H) qRT-PCR quantification of CD36 in the HCT116 p-Lenti-Control and
CD36-Overexpression cell lines. * p < 0.05, ** p < 0.01, *** p < 0.001; SEM.
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We have performed RNA-Seq analysis on parental HT29 p-Lenti-Control and p-LentiCD36 overexpression cell lines. The full list of DEGs in these two cell lines is included as
Figure S1. Gene set enrichment analysis shows an enrichment of genes involving focal
adhesion, gap junction and cancer-associated pathways in HT29 p-Lenti-CD36 overexpression cell line as compared to the HT29 p-Lenti-Control (Figure 4A). The top 10 enriched
pathway sets are provided in Figure S2. Interestingly, we found that CD36 expression is
associated with matrix metallopeptidase 28 (MMP28) (Figure 4B). MMP28 is the newest
member matrix metallopeptidase to be identified and is involved in ECM degradation [36].
MMP28 is associated with metastasis in lung and gastric cancer [36,39], but has not yet
been studied in CRC. To confirm the RNA-Seq data, we performed qRT-PCR analysis of
the HT29 and HCT116 cells (p-Lenti-Control and p-Lenti-CD36 overexpression) and HT29
LuM3 and HCT116 cells (NTC and CD36 shRNA). As shown in Figure 4C, overexpression
of CD36 in HT29 cells leads to significant upregulation of MMP28 mRNA. In contrast,
shRNA-mediated knockdown of CD36 in HT29 LuM3 cells leads to a decrease in MMP28
mRNA expression. Consistent with these results, HCT116 cells with CD36 overexpression
also exhibit higher levels of MMP28 mRNA expression and, inversely, HCT116 CD36
shRNA cells show a significant decrease in MMP28 mRNA expression (Figure 4D). Furthermore, the HCT116 and HT29 LuM0 cell lines with CD36 overexpression also display
higher protein expression of MMP28, and the pro-survival marker p-Akt (Figure 4E) [43].
To further support the association between CD36 and MMP28, we show that HT29 LuM3
cells, which express higher levels of CD36, also express higher levels of MMP28 protein
compared to the parental HT29 LuM0 cell line, as shown by Western blot and confocal
microscopy (Figure 4F,G).
Together these data demonstrate that upregulation of CD36 upregulates expression
9 ofof18
MMP28 at the mRNA and protein levels.

Figure 4. Cont.

Figure 4. CD36 regulates expression of MMP28. (A) Representative gene set enrichment analysis
(GSEA) plots generated from RNA‐Seq expression data of the HT29 p‐Lenti Control and HT29 p‐
Lenti CD36 overexpression cell lines. The top 10 enriched pathway sets are provided in Figure S2.
Bar codes indicate the location of gene set members in the ranked list of all genes. ES, enrichment
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HT29 LuM3 GFP-Luciferase cell lines. (G) Confocal microscopy of the HT29 LuM0 and HT29 LuM3
*** p < 0.001; SEM.
GFP-Luciferase cell lines for actin, CD36 and MMP28. * p < 0.05, ** p < 0.01, *** p < 0.001; SEM.

Together
these data
thatReduces
upregulation
of CD36
upregulates
expression
3.5. MMP28
Promotes
CRC demonstrate
Cell Invasion and
Expression
of E-Cadherin
In Vitro
of MMP28 at the mRNA and protein levels.
Previously published data suggest that MMP28 plays a critical role in the regulation
of metastasis in lung and gastric cancers. Specifically, MMP28 has been shown to promote
3.5. MMP28 Promotes CRC Cell Invasion and Reduces Expression of E‐Cadherin In Vitro
EMT in lung carcinoma and increased expression of MMP28 is associated with a loss of
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[36,39].published
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using two
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(Figure
5A). Furthermore,
decrease cells
in MMP28
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expression
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to transfection
with MMP28 siRNA leads to a significant increase in mRNA expression of E-cadherin
when compared to cells transfected with scrambled siRNA control (Figure 5B). Western
blot analysis of the HT29-LuM3-GFP-Luciferase NTC and CD36 shRNA knockdown cell
lines demonstrates a reduction in MMP28 expression and an increase in E-cadherin expression (135 kD) (Figure 5C). Additionally, this analysis shows a decrease in the product of
E-cadherin cleavage, CTF1(38kD), in the CD36 knockdown cell line (Figure 5C). siRNAmediated knockdown of MMP28 in HT29LM3 cells trained to metastasize to liver [44]
and HT29LuM3 cells also leads to upregulation of E-cadherin expression and a decrease
in CTF1 (Figure 5D). To further investigate the effect of MMP28 on E-cadherin cleavage,
we performed Western blot analysis of HCT116 cells transfected with MMP28 siRNA versus HCT116 control cells. We found that MMP28 is not only associated with a decrease
in functional E-cadherin (135 kD) but also associated with an increase in two cleavage
products of E-cadherin, CTF1 and CTF2 (33 kD). Inhibition of MMP28 expression is associated with almost complete abolishment of E-cadherin cleavage (Figure 5D), suggesting
that MMP28 plays a crucial role in the regulation of E-cadherin, potentially via direct
cleavage. These data further support the hypothesis that MMP28 regulates expression of
E-cadherin downstream of CD36 and indicates MMP28 may be involved in direct cleavage
of E-cadherin.

Cancers2022,
2022,14,
14,252
x
Cancers

11 of
of 17
18
10

Figure 5.
5. MMP28
and
decreases
expression
of functional
E-cadherin
in
Figure
MMP28reduces
reducesCRC
CRCcell
cellinvasion
invasion
and
decreases
expression
of functional
E-cadherin
vitro.
(A)
Fold
change
in
invaded
cells/field,
absorbance
at
560
nm
of
the
de-stained
Matrigel
in vitro. (A) Fold change in invaded cells/field, absorbance at 560 nm of the de-stained Matrigel
trans-well invasion chambers and raw images of the Matrigel trans-well invasion chambers of the
trans-well invasion chambers and raw images of the Matrigel trans-well invasion chambers of the
HCT116, siControl and siMMP28 cell lines (n = 3). (B) Western blot analysis of the HT29 LuM3
HCT116, siControl and siMMP28 cell lines (n = 3). (B) Western blot analysis of the HT29 LuM3 NTC
NTC and shCD36 cell lines for CD36, MMP28 and E-cadherin. The long exposure of the same
and
shCD36
for CD36,
MMP28
and(C)
E-cadherin.
The for
longMMP28
exposure
ofE-cadherin
the same Western
blot
Western
blotcell
forlines
E-cadherin
is also
shown.
Western blot
and
expression
for
E-cadherin
is
also
shown.
(C)
Western
blot
for
MMP28
and
E-cadherin
expression
in
HT29LM3
in HT29LM3 and HT29LuM3 cells. Western blot including the E-cadherin cleavage products CTF1
and
cells.
blot
including
the E-cadherin
cleavage
products
CTF1
and CTF2
and HT29LuM3
CTF2 is shown
onWestern
a separate
blot
(long exposure).
(D) qRT-PCR
analysis
of the
control
and is
shown
a separate
blot (long
exposure).
(D)for
qRT-PCR
of the control
and MMP28
siRNA
MMP28onsiRNA
transfected
HCT116
cell lines
MMP28analysis
and E-cadherin.
(E) Western
blot for
MMP28 and
E-cadherin
expression
in HCT116
cells. Western
blot including
the E-cadherin
cleavtransfected
HCT116
cell lines
for MMP28
and E-cadherin.
(E) Western
blot for MMP28
and E-cadherin
age products
CTF1 and
CTF2
is shown
separatethe
blots
(long and
short exposure).
(F) Western
expression
in HCT116
cells.
Western
bloton
including
E-cadherin
cleavage
products CTF1
and CTF2
blot
analysis
showingblots
the effect
CD36
blocking
antibody
on E-cadherin
expression
in HT29
is
shown
on separate
(longofand
short
exposure).
(F) Western
blot analysis
showing
the effect
LuM0, HT29LuM3 and HCT116 cells. Expression of E-cadherin is quantified based on band intenof CD36 blocking antibody on E-cadherin expression in HT29 LuM0, HT29LuM3 and HCT116 cells.
sity and normalized to actin. (G) Western blot analysis showing the effect of CD36 blocking antiExpression of E-cadherin is quantified based on band intensity and normalized to actin. (G) Western
body on e-cadherin and MMP28 expression in HCT116 cells treated with IgA or IgCD39 for 48 h in
blot
analysis
showing
the(*effect
of CD36
normal
medium
or SFM
p < 0.05,
** p <blocking
0.01, *** antibody
p < 0.001).on e-cadherin and MMP28 expression in
HCT116 cells treated with IgA or IgCD39 for 48 h in normal medium or SFM (* p < 0.05, ** p < 0.01,
*** p < 0.001).

Cancers 2022, 14, 252

11 of 17

The levels of E-cadherin expression can be regulated transcriptionally or by E-cadherin
cleavage and shedding [33]. We have not identified any modes of transcriptional regulation,
such as through the E-cadherin regulators Slug or Snail [32,33], in response to altered
expression of CD36 or MMP28.
To confirm that CD36 regulates E-cadherin via FA uptake, we treated HT29LuM0,
HT29LuM3 and HCT116 cells with anti-CD36 blocking antibody. Inhibition of exogenous
FA uptake increased the expression of E-cadherin starting at 24 h treatment in HT29LuM0
and HCT116 cells and 48 h treatment in HT29LuM3 cells (Figure 5F). We have previously
shown that exposure of CRC cells to serum-free medium (SFM) upregulates CD36 expression [15]. Here, we show that both SFM and anti-CD36 blocking antibody treatment of
HCT116 cells upregulates CD36 expression. However, blocking of CD36 with antibody
upregulates the expression of E-cadherin in normal medium, but not in SFM (Figure 5G),
further suggesting that the effect of CD36 on E-cadherin expression is FA uptake dependent.
No significant changes in MMP28 expression were observed.
Together, these data suggest that CD36 increases the invasive and metastatic potential
of CRC cells via induction of MMP28 and transcriptional downregulation and cleavage
of E-cadherin.
3.6. Overexpression of CD36 Is Associated with an Increase in MMP28 Expression and Reduction
of E-Cadherin In Vivo and Human CRC Specimens
To support our data on the CD36–MMP28–E-cadherin axis in CRC metastasis, we
analyzed the expression of CD36, MMP28 and E-cadherin in lung tissues resected from
mice injected with HT29 LuM3, NTC and CD36 shRNA cells (Figure 3A). IHC analysis
demonstrates that a reduction in CD36 and MMP28 expression is associated with an
increase in E-cadherin expression in tumor lesions with CD36 knockdown, as compared to
NTC tumor tissues (Figure 6A).
Our laboratory has previously shown that isogenic patient-derived xenograft (PDX)
tumors, which were established from isolating tumor cells expressing high levels of CD36
(CD36high ), have a higher propensity to grow subcutaneous tumors in vivo [15]. To further
confirm the relationship between CD36, MMP28 and E-cadherin, we analyzed tissues from
Pt2402 CD36high and CD36low PDXs. Western blot analysis and IHC staining confirms that
low expression of CD36 is associated with low expression of MMP28 and an increase in the
level of E-cadherin (Figure 6B,C).
To translate our in vitro and in vivo findings to human tissues, we analyzed the
expression of CD36, MMP28 and E-cadherin in matched normal mucosa, primary CRC and
liver metastasis specimens. Our data show that as we transition from normal tissue to a
primary tumor and then metastasis, we see an increase in the expression of both CD36 and
MMP28 (Figure 6D). Furthermore, an analysis of matched normal mucosa, primary CRC
and CRC liver metastasis demonstrates and an increase in expression of CD36 and MMP28
and a decrease in the expression of E-cadherin as we move from normal tissues to primary
and metastatic tumors. In agreement with our in vitro data, these human tissues also show
an increase in the cleavage product of E-cadherin, CTF2, as disease progresses, suggesting
that MMP28, through CD36 regulation, may directly cleave E-cadherin (Figure 6D,E).
In summary, our data suggest that CD36 upregulates MMP28 expression, inducing
E-cadherin loss in vivo and in human tissues.
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from Pt2402 CD36high and CD36low PDXs. Western blot analysis and IHC staining confirms
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4. Discussion
Previous investigation from our laboratory has revealed that CD36 plays an important
role in the survival and proliferation of CRC cells and its specific upregulation may be
a potential compensation mechanism when de novo fatty acid synthesis is inhibited in
CRC [15]. Aside from its pro-survival and tumorigenic properties, CD36 has been implied
in the promotion of invasion and metastasis of multiple types of cancer [11,13,16–18].
Despite this knowledge, the role of CD36 in the process of invasion and metastasis of CRC
has not yet been investigated.
In parallel with previous reports that suggest CD36 promotes invasion and metastasis
of ovarian and gastric cancer cells, we found that CD36 promotes colony formation and
trans-well invasion of CRC cells in vitro [11,17]. Consistent with these findings, we show
that CRC cells, which exhibit a more metastatic phenotype, express higher levels of CD36
and uptake more exogenous fatty acids in a CD36-dependent fashion.
One of the premier studies investigating the role of CD36 in metastasis was that of
Pascual et al., which described the pro-metastatic characteristic of CD36 in oral carcinoma.
It was reported that a subpopulation of oral carcinoma cells that express high levels of CD36
were unique in their ability to initiate metastasis in vivo [16]. Additionally, they found
that knockdown or inhibition of CD36 did not affect oral carcinoma primary xenograft
tumor growth, but almost completely abolished local invasion [16]. In contrast to their
findings, our previous study showed that CD36 does play an important role in primary CRC
tumor growth, in particular when endogenously synthesized fatty acids are limited [15].
However, our current study is in agreement with their findings on metastasis, suggesting
that CD36 is also critical for CRC invasion and metastasis. Consequently, our findings
here are also in parallel with several other studies showing that CD36 promotes metastasis
in vivo [11,13,16,17].
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It is worth noting that due to the role of CD36 in the survival and proliferation of
CRC cells, it is possible that this may also be responsible for the effect of CD36 on CRC
metastasis. Therefore, it is critically important to identify a potential mechanistic pathway
that distinguishes the pro-survival characteristics of CD36 from any pro-metastatic ones.
Previously we described that CD36 is associated with increased levels of the pro-survival
marker survivin in primary CRC [15]. We also showed that an increase in the expression of
CD36 increases phosphorylation of Akt [15]. The Akt pathway is implicated in regulation of
both cancer cell survival and metastasis [43]. A previously published study has implicated
that CD36 promotes metastatic disease in gastric cancer via the Akt/GSK-3β/β-catenin
pathway [17]. Consistent with this study, we show that overexpressing CD36 increases
cell invasion and colony formation and is associated with increased levels of p-Akt in
established CRC cell lines. However, an increase in phosphorylation of Akt alone is not
sufficient to describe a metastatic advantage for CRC.
As previously mentioned, the process of EMT is recognized as one of the crucial steps
involved in cancer metastasis and a hallmark of cancer [22,23,45]. The remodeling of the
extracellular matrix is critical for cells to escape their primary environment and enter the
systemic circulation (blood or lymphatic system) where they then travel to distant sites and
colonize new metastatic tumors [22]. It has been previously shown that increased fatty acid
uptake via CD36 is associated with EMT progression in hepatocellular carcinoma cells [46].
Furthermore, CD36 has been shown to promote EMT in cervical cancer through interactions
with the TGF-β pathway [18]. More specifically, treatment of cervical cancer cells with
TGF-β increased CD36 expression and exhibited a significant loss in the expression of
E-cadherin [18]. Loss of E-cadherin is a critical marker for EMT and a well-established
hallmark of cancer [22]. Interestingly, our studies show that overexpression of CD36
promotes loss of E-cadherin through a relatively novel member of the MMP family of
proteins, MMP28.
A few members of the MMP family of proteins have been linked to EMT in multiple
diseases [47–49]. Particularly, MMP-3 and 7 have been shown to promote EMT in breast
cancer cells in vitro through direct cleavage of E-cadherin [47,49]. In most studies, those
tumors expressing higher levels of various MMPs result in a poor prognosis for patient
survival [48]. MMP28 is associated with EMT in lung carcinoma [36]. Additionally, MMP28
is associated with invasion and colony formation in gastric cancer cells and increased
MMP28 expression is a poor prognostic factor for gastric cancer patients [37,38]. Our studies
show here, for the first time, that overexpression of CD36 increases MMP28 expression and
that MMP28 promotes CRC cell invasion. We also show here that expression of both CD36
and MMP28 is associated with a loss of the critical EMT marker E-cadherin in CRC cell
lines. Along with this loss of E-cadherin, MMP28 expression is associated with increased
levels of the cleaved C-terminal fragments of E-cadherin—CTF1 and CTF2 [50]. CTF1
contains both the transmembrane and cytoplasmic domains of E-cadherin and is produced
after cleavage [51]. CTF1 can then be processed further, resulting in the release of CTF2,
which is just the cytoplasmic domain of E-cadherin [50,51]. Our data show that MMP28mediated E-cadherin cleavage is cell-type dependent and seems to be more prominent in
HCT116 cells.
Aside from simply being cleavage products of E-cadherin, the CTFs themselves can
act as downstream signaling molecules, such as interacting with and preventing β-catenin
degradation as well as aiding in the translocation of β-catenin to the nucleus, promoting
transcription of various downstream genes [52]. Because of the prominent role the Wnt/βcatenin pathway plays in CRC, further investigation into the MMP28–E-cadherin–CTF
association described here may yield greater information on the mechanisms of CRC
progression and metastasis.
Clinically, obesity has been linked to increased risk of metastasis in many cancer types,
including CRC [53]. However, the link between high-fat diet, obesity and metastasis is
not well understood. A 2017 study showed that dietary lipids enhanced the ability of the
CD36 subpopulation of oral carcinoma cells to metastasize and treatment with anti-CD36
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neutralizing antibodies inhibited metastasis initiation and induced significant regression of
established oral carcinoma metastases [16]. Consistent with these data, using anti-CD36
neutralizing antibody, we show that the effect of CD36 on E-cadherin loss is, at least in part,
mediated by FA uptake. However, we also noted that blocking of CD36 with antibody did
significantly impact expression of MMP28 and E-cadherin shedding as compared to CD36
and MMP28 downregulation via shRNA and siRNA approaches, respectively. The potential
explanation for this is that CD36 regulates MMP28 primarily via intracellular mechanisms
independent of its function as a FA transporter. Indeed, several studies showed that besides
functioning on the membrane as a FA transporter, CD36 may play other roles such as
facilitating intracellular traffic of FAs and increasing the rate of intracellular esterification
and, thus, regulating cellular signaling and metabolism without catalyzing the translocation
of FAs across the plasma membrane [54–56]. To support the intracellular role of CD36, our
published work shows a significant increase in cytosolic CD36 staining in tumor tissues as
compared to normal mucosa [15].
Results of the current study show that CD36 regulates E-cadherin through both transcriptional regulation and proteolytic processing via MMP28, suggesting that upregulation
of MMP28 expression by overexpression of CD36 followed by E-cadherin shedding may be
independent of FA uptake via CD36. CD36-targeted therapies, including CD36 neutralizing
antibodies, have been in development, but knowledge gaps about the multiple roles of
this protein in cancer cells as well as in the tumor microenvironment must be filled before
further advancements can be made towards clinical practice [57]. Furthermore, our results
presented in the current manuscript warrant additional mechanistic studies to delineate FA
uptake dependent and independent of CD36 on metastasis. Another limitation of the current study is that the direct effect of a CD36-blocking antibody was not tested in functional
assays or in vivo. We plan to delineate the link between high-fat diet, CD36-mediated
uptake of FA uptake and CRC metastasis in our future studies.
Aside from showing a direct relationship between MMP28 and E-cadherin, we more
importantly show that MMP28 downregulation via reduced expression of CD36 significantly upregulates E-cadherin, not only in established CRC cell lines, but also in isogenic
PDXs and patient tissues. To our knowledge, this is the first study to demonstrate that
CD36 upregulates MMP28 expression and loss of E-cadherin. Our study is also the first
to suggest that MMP28 may be directly involved in the cleavage of E-cadherin in CRC.
Therefore, the data presented here show that CD36 might play an important role in the
regulation of metastasis in CRC through the upregulation of MMP28 and loss of E-cadherin.
5. Conclusions
Late-stage CRC, categorized by advanced disease with distant metastasis, remains
one of the deadliest cancers in the United States and indeed the world [1]. New therapeutic
strategies to identify and target tumor cells with higher metastatic potential are needed to
improve the efficacy of treatment and increase overall patient survival. Together, this study
highlights the potential of both CD36 and MMP28 as therapeutic targets for CRC. Further
investigation into the exact mechanistic regulation of MMP28 by CD36 and MMP28’s
interaction with E-cadherin is needed to potentially develop new, more effective treatment
strategies for patients with late-stage CRC or other solid malignancies.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/cancers14010252/s1, Figure S1: List of DEGs in HT29 control vs.
HT29 CD36 overexpression cells, Figure S2: Positively and negatively enriched pathways in HT29
control vs. HT29 CD36 overexpression cells.
Author Contributions: Conceptualization, J.D., B.M.E. and Y.Y.Z.; methodology, J.D., P.G.R., C.O.K.
and M.E.G.; validation, J.D.; formal analysis, J.D., P.G.R., Y.W., D.H., C.W. and E.Y.L.; investigation,
J.D. and Y.Y.Z.; resources, P.G.R., Y.W., D.H., C.W., E.Y.L. and B.M.E.; data curation, J.D.; writing—
original draft preparation, J.D.; writing—review and editing, J.D. and Y.Y.Z.; supervision, J.D. and

Cancers 2022, 14, 252

15 of 17

Y.Y.Z.; project administration, Y.Y.Z.; funding acquisition, Y.Y.Z. All authors have read and agreed to
the published version of the manuscript.
Funding: This research was funded by NCI R01 CA249734 (Y.Y.Z.) and NCI R01 CA208343 (B.M.E.).
Data Availability Statement: All data included in the manuscript or in the supplemental material
are available upon request.
Acknowledgments: Markey Cancer Center’s Biospecimen Procurement and Translational Pathology
Shared Resource Facility (SRF) aided in preparation of tissue slides for immunohistochemistry,
and the Biostatistics and Bioinformatics SRF provided statistical analysis of all data (both SRFs are
supported by National Cancer Institute grant P30 CA177558). The Markey Cancer Center’s Research
Communications Office assisted with manuscript preparation.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.

5.
6.
7.
8.
9.
10.

11.

12.

13.
14.
15.

16.
17.
18.
19.

Ferlay, J.; Shin, H.-R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008:
GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893–2917. [CrossRef]
Siegel, R.L.; Miller, K.D.; Goding Sauer, A.; Fedewa, S.A.; Butterly, L.F.; Anderson, J.C.; Cercek, A.; Smith, R.A.; Jemal, A.
Colorectal cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 145–164. [CrossRef] [PubMed]
American Cancer Society. Cancer Facts & Figures. 2021. Available online: https://www.cancer.org/cancer/colon-rectal-cancer/
detection-diagnosis-staging/survival-rates.html#references (accessed on 15 March 2021).
Howlader, N.A.; Krapcho, M.; Miller, D.; Brest, A.; Yu, M.; Ruhl, J.; Tatalovich, Z.; Mariotto, A.; Lewis, D.R.; Chen, H.S.;
et al. (Eds.) SEER Cancer Statistics Review, 1975–2017; National Cancer Institute: Bethesda, MD, USA, 2020. Available online:
https://seer.cancer.gov/csr/1975_2017/ (accessed on 7 March 2021).
Pavlova, N.N.; Thompson, C.B. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016, 23, 27–47. [CrossRef] [PubMed]
Buckley, D.; Duke, G.; Heuer, T.S.; O’Farrell, M.; Wagman, A.S.; McCulloch, W.; Kemble, G. Fatty acid synthase—Modern tumor
cell biology insights into a classical oncology target. Pharmacol. Ther. 2017, 177, 23–31. [CrossRef]
Currie, E.; Schulze, A.; Zechner, R.; Walther, T.C.; Farese, R.V. Cellular Fatty Acid Metabolism and Cancer. Cell Metab. 2013, 18,
153–161. [CrossRef] [PubMed]
Pepino, M.Y.; Kuda, O.; Samovski, D.; Abumrad, N.A. Structure-Function of CD36 and Importance of Fatty Acid Signal
Transduction in Fat Metabolism. Annu. Rev. Nutr. 2014, 34, 281–303. [CrossRef]
Glatz, J.F.C.; Luiken, J.J.F.P. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and
utilization. J. Lipid Res. 2018, 59, 1084–1093. [CrossRef]
Drover, V.A.; Nguyen, D.V.; Bastie, C.; Darlington, Y.F.; Abumrad, N.A.; Pessin, J.E.; London, E.; Sahoo, D.; Phillips, M.C. CD36
Mediates Both Cellular Uptake of Very Long Chain Fatty Acids and Their Intestinal Absorption in Mice. J. Biol. Chem. 2008, 283,
13108–13115. [CrossRef] [PubMed]
Ladanyi, A.; Mukherjee, A.; Kenny, H.A.; Johnson, A.; Mitra, A.K.; Sundaresan, S.; Nieman, K.M.; Pascual, G.; Benitah, S.A.;
Montag, A.; et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene 2018, 37,
2285–2301. [CrossRef]
Jayawardhana, A.M.D.S.; Stilgenbauer, M.; Datta, P.; Qiu, Z.; Mckenzie, S.; Wang, H.; Bowers, D.; Kurokawa, M.; Zheng, Y.-R.
Fatty acid-like Pt(iv) prodrugs overcome cisplatin resistance in ovarian cancer by harnessing CD36. Chem. Commun. 2020, 56,
10706–10709. [CrossRef]
Hale, J.S.; Otvos, B.; Sinyuk, M.; Alvarado, A.G.; Hitomi, M.; Stoltz, K.; Wu, Q.; Flavahan, W.; Levison, B.; Johansen, M.L.; et al.
Cancer Stem Cell-Specific Scavenger Receptor CD36 Drives Glioblastoma Progression. Stem. Cells 2014, 32, 1746–1758. [CrossRef]
Zhao, J.; Zhi, Z.; Wang, C.; Xing, H.; Song, G.; Yu, X.; Zhu, Y.; Wang, X.; Zhang, X.; Di, Y. Exogenous lipids promote the growth of
breast cancer cells via CD36. Oncol. Rep. 2017, 38, 2105–2115. [CrossRef]
Drury, J.; Rychahou, P.G.; He, D.; Jafari, N.; Wang, C.; Lee, E.Y.; Weiss, H.L.; Evers, B.M.; Zaytseva, Y.Y. Inhibition of Fatty
Acid Synthase Upregulates Expression of CD36 to Sustain Proliferation of Colorectal Cancer Cells. Front. Oncol. 2020, 10, 1185.
[CrossRef] [PubMed]
Pascual, G.; Avgustinova, A.; Mejetta, S.; Martín, M.; Castellanos, A.; Attolini, C.S.; Berenguer, A.; Prats, N.; Toll, A.; Hueto, J.A.;
et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 2017, 541, 41–45. [CrossRef] [PubMed]
Pan, J.; Fan, Z.; Wang, Z.; Dai, Q.; Xiang, Z.; Yuan, F.; Yan, M.; Zhu, Z.; Liu, B.; Li, C. CD36 mediates palmitate acid-induced
metastasis of gastric cancer via AKT/GSK-3β/β-catenin pathway. J. Exp. Clin. Cancer Res. 2019, 38, 1–15. [CrossRef]
Deng, M.; Cai, X.; Long, L.; Xie, L.; Ma, H.; Zhou, Y.; Liu, S.; Zeng, C. CD36 promotes the epithelial–mesenchymal transition and
metastasis in cervical cancer by interacting with TGF-β. J. Transl. Med. 2019, 17, 1–10. [CrossRef] [PubMed]
Yang, P.; Su, C.; Luo, X.; Zeng, H.; Zhao, L.; Wei, L.; Zhang, X.; Varghese, Z.; Moorhead, J.F.; Chen, Y.; et al. Dietary oleic
acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway. Cancer Lett. 2018,
438, 76–85. [CrossRef]

Cancers 2022, 14, 252

20.
21.
22.
23.
24.

25.
26.
27.

28.
29.
30.
31.
32.
33.

34.

35.
36.
37.
38.
39.
40.
41.

42.
43.
44.
45.
46.
47.

16 of 17

Kalluri, R.; Neilson, E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 2003, 112, 1776–1784.
[CrossRef]
Kalluri, R.; Weinberg, R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420–1428. [CrossRef]
Zhang, Y.; Weinberg, R.A. Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities. Front. Med. 2018, 12,
361–373. [CrossRef]
Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits.
Nat. Rev. Cancer 2009, 9, 265–273. [CrossRef] [PubMed]
Ocaña, O.H.; Córcoles, R.; Fabra, Á.; Moreno-Bueno, G.; Acloque, H.; Vega, S.; Barrallo-Gimeno, A.; Cano, A.; Nieto, M.A.
Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. Cancer Cell 2012, 22,
709–724. [CrossRef]
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